Cardiac Surgery Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for cardiac surgery. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.

Questions? See the Clinical Trials FAQs.

Key Inclusion Criteria:

Normal Control and HypoE

  • Premenopausal, not on hormone therapy
  • Has missed three or more monthly menstrual cycles in a row or has normal monthly menstrual cycles
  • English speaking (for the purposes of complete self-assessments)
  • Able to give informed consent
  • Between 18-40 years old

Menopause

  • Recently menopausal (within three years of final menstrual period)
  • English speaking (for the purposes of complete self-assessments)
  • Able to give informed consent
  • 50 years of age or older
  • Has not taken hormone replacement therapy or estrogen since entering menopause

Summary:

The Barbra Streisand Women's Heart Center invites you to participate in a new study designed to evaluate the impact of estrogen on your heart health. We know that low estrogen levels are not healthy in young women, and we want to see if it will affect your heart health in the future.

Caisson Transcatheter Mitral Valve Replacement (TMVR) System Early Feasibility Study (PRELUDE)

Condition: 

Mitral Valve Regurgitation

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

Condition: 

Aortic Valve Disease, Aortic Valve Stenosis

Condition: 

Atherosclerotic cardiovascular disease, hypercholesterolemia

Key Inclusion Criteria:

  • Evidence by cardiac computed tomography angiography of noncalcified coronary artery plaque and thoracic aorta atherosclerosis 
  • Indications for evolocumab treatment

Summary:

This study focuses on patients who have clinical atherosclerotic cardiovascular disease (ASCVD) or high cholesterol levels and are allergic to statins, or who have been diagnosed with primary hypercholesterolemia or homozygous familial hypercholesterolemia (genetic disorder causing high cholesterol levels and early heart disease). The purpose of the study is to evaluate the changes, if any, in coronary plaque volumes and its composition in patients who are treated with a drug called evolocumab. To help evaluate the effect of evolocumab, researchers will ask patients who are scheduled to start taking evolocumab plus another cholesterol-lowering medication (such as a statin) to undergo diagnostic testing, including non-invasive coronary computed tomography angiography scans and positron emission tomography (PET) scans.

Condition: 

Coronary artery disease

Key Inclusion Criteria:

  • At least 18 years old
  • Scheduled to undergo an invasive coronary angiography for the assessment of coronary artery disease at the time of enrollment
  • Signed consent form and willing to allow researchers to make medical records available to GE Healthcare

Summary:

This study focuses on patients who are scheduled to have an invasive coronary angiography (cardiac catheterization) as part of their standard of care. The purpose of the study is to evaluate how well an investigational imaging drug called flurpiridaz (F-18) can detect coronary artery disease. Coronary artery disease is a condition that decreases blood flow to the heart.

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Condition: 

Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy

Condition:

Atherosclerosis

Key Inclusion Criteria:

  • Recent myocardial infarction, ischemic stroke, or onset of symptomatic lower extremity peripheral artery disease less than 3 months before study enrollment
  • Recent or planned prescription of statin and antiplatelet therapy within 3 months of study recruitment

Summary:

This study focuses on patients who have recently had a heart attack, stroke or symptomatic peripheral artery disease. The purpose of the study is to measure plaque in multiple arteries in the body and evaluate their characteristics. Researchers will obtain these measurements to examine the ability of magnetic resonance imaging (MRI) to assess cardiovascular risk. Participants will undergo MRI of the carotid, coronary and femoral arteries; pulse wave analysis (a noninvasive clinical test) to measure stiffness of the blood vessels; and blood collection. They will also be asked to complete questionnaires.

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) (MAVERICK-HCM)

Condition: 

Non-obstructive Hypertrophic Cardiomyopathy

Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment

Condition: 

Cardiovascular Disease, Atherosclerosis

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Condition: 

Cardiac Surgery

Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Condition: 

Coronary Microvascular Dysfunction

Women's Heart Attack Research Program—Imaging Study (HARP)

Condition:

Myocardial Infarction